SCHEMBL160304

SCHEMBL160304

Nc1ncnc2[nH]c([SeH])nc12

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.40
ADORA1 P30542 3/20 0.40
ERAP1 Q9NZ08 1/20 0.39
PI4KA P42356 7/20 0.37
PI4K2B Q8TCG2 7/20 0.37
PI4K2A Q9BTU6 7/20 0.37
PI4KB Q9UBF8 7/20 0.37
NUDT1 P36639 2/20 0.37
XDH P47989 2/20 0.35
LRRK2 Q5S007 2/20 0.35
RET P07949 1/20 0.35
LMNA P02545 1/20 0.35
DRD3 P35462 1/20 0.35
PIK3CG P48736 1/20 0.35
ADORA2B P29275 1/20 0.34
MAP4K4 O95819 1/20 0.34
LIMK1 P53667 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL42313 0.78 ADORA2A (0.42) ADORA2AADORA1ERAP1PI4KAPI4K2B
SCHEMBL42336 0.75 PIK3CG (0.42) ADORA2AADORA1ERAP1PI4KAPI4K2B
SCHEMBL159639 0.75 ADORA2A (0.40) ADORA2AADORA1ERAP1PI4KAPI4K2B
SCHEMBL843216 0.75 ADORA2A (0.40) ADORA2AADORA1ERAP1PI4KAPI4K2B
SCHEMBL4581404 0.75 PI4KA (0.41) ADORA2AADORA1ERAP1PI4KAPI4K2B
SCHEMBL8565 0.75 ADORA2A (0.58) ADORA2AADORA1ERAP1PI4KAPI4K2B
SCHEMBL842439 0.75 ADORA2A (0.40) ADORA2AADORA1ERAP1PI4KAPI4K2B
SCHEMBL12620888 0.75 ADORA2A (0.40) ADORA2AADORA1ERAP1PI4KAPI4K2B
SCHEMBL953009 0.75 NUDT1 (0.41) ADORA2AADORA1ERAP1PI4KAPI4K2B
SCHEMBL842890 0.75 ADORA2A (0.40) ADORA2AADORA1ERAP1PI4KAPI4K2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150157655-A1 SELENIUM CONTAINING NUCLEOSIDES AS NUTRITIONAL SUPPLEMENTS SENA RESEARCH, INC. (US) 2015-06-11 US claimed
WO-2014003950-A2 SELENIUM CONTAINING NUCLEOSIDES AS NUTRITIONAL SUPPLEMENTS SENA RESEARCH, INC. (US) 2014-01-03 WO claimed
US-7982030-B2 Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2011-07-19 US claimed
US-20100137573-A1 SYNTHESIS OF SELENIUM-DERIVATIZED NUCLEOSIDES, NUCLEOTIDES, PHOSPHORAMIDITES, TRIPHOSPHATES AND NUCLEIC ACIDS GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2010-06-03 US claimed
US-20030055016-A1 Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-03-20 US claimed
WO-2002077002-A2 SYNTHESIS OF SELENIUM-DERIVATIZED NUCLEOSIDES, NUCLEOTIDES, PHOSPHORAMIDITES, TRIPHOSPHATES AND NUCLEIC ACIDS RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2002-10-03 WO claimed
US-4617189-A Use of selenium-containing compounds for negating the toxic effects of platinum compounds used in chemotherapy, and a novel selenium-containing platinum compound and use thereof as an anti-cancer medicine STOCKEL RICHARD F (US) 1986-10-14 US claimed
US-10337030-B2 Microbially-mediated method for synthesis of metal chalcogenide nanoparticles UT-BATTELLE, LLC (US) 2019-07-02 US disclosed
US-9909221-B2 Controllable reductive method for synthesizing metal-containing particles UT-BATTELLE, LLC (US) 2018-03-06 US disclosed
US-20180010153-A1 MICROBIALLY-MEDIATED METHOD FOR SYNTHESIS OF METAL CHALCOGENIDE NANOPARTICLES U.S. DEPARTMENT OF ENERGY 2018-01-11 US disclosed
US-9768333-B2 Microbially-mediated method for synthesis of non-oxide semiconductor nanoparticles UT-BATTELLE, LLC (US) 2017-09-19 US disclosed
US-9637828-B2 Electrochemical method for synthesizing metal-containing particles and other objects UT-BATTELLE, LLC (US) 2017-05-02 US disclosed
US-9196760-B2 Methods for producing complex films, and films produced thereby UT-BATTELLE, LLC (US) 2015-11-24 US disclosed
US-20100193752-A1 MICROBIALLY-MEDIATED METHOD FOR SYNTHESIS OF NON-OXIDE SEMICONDUCTOR NANOPARTICLES UT-BATTELLE, LLC (US) 2010-08-05 US disclosed
US-20100137573-A1 SYNTHESIS OF SELENIUM-DERIVATIZED NUCLEOSIDES, NUCLEOTIDES, PHOSPHORAMIDITES, TRIPHOSPHATES AND NUCLEIC ACIDS GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2010-06-03 US disclosed
US-7592446-B2 Useful in structural determinations, particularly by X-ray crystallographic techniques; useful as food supplements GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2009-09-22 US disclosed
US-20030055016-A1 Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-03-20 US disclosed
WO-2002077002-A2 SYNTHESIS OF SELENIUM-DERIVATIZED NUCLEOSIDES, NUCLEOTIDES, PHOSPHORAMIDITES, TRIPHOSPHATES AND NUCLEIC ACIDS RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2002-10-03 WO disclosed
US-4617189-A Use of selenium-containing compounds for negating the toxic effects of platinum compounds used in chemotherapy, and a novel selenium-containing platinum compound and use thereof as an anti-cancer medicine STOCKEL RICHARD F (US) 1986-10-14 US disclosed
US-4536571-A SEFL-DETOXIFYING ANTICARCINOGENIC AGENT STOCKEL RICHARD F (US) 1985-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055016-A1 Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids SELENOI, NT5C3B, RNGTT ADORA2A 255/4885ADORA1 551/4885ERAP1 704/4885
US-20100137573-A1 SYNTHESIS OF SELENIUM-DERIVATIZED NUCLEOSIDES, NUCLEOTIDES, PHOSPHORAMIDITES, TRIPHOSPHATES AND NUCLEIC ACIDS SELENOI, RNGTT, NT5C3B ADORA2A 216/4885ADORA1 430/4885ERAP1 836/4885
US-20150157655-A1 SELENIUM CONTAINING NUCLEOSIDES AS NUTRITIONAL SUPPLEMENTS SLC28A1, SLC28A2, SLC5A6 ADORA2A 628/4885ADORA1 1489/4885ERAP1 989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.